Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  10:15:39 2023-01-27 am EST
0.0293 CHF   -1.01%
01/17RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
CI
01/17Relief Therapeutics Wins Review Board's Nod for Planned Clinical Study of Skin Cancer Drug
MT
01/17Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 873274130130-
Enterprise Value (EV)1 873274130130130
P/E ratio -----
Yield -----
Capitalization / Revenue -61,1x10,9x5,66x2,96x
EV / Revenue -61,1x10,9x5,66x2,96x
EV / EBITDA -43,1x-8,50x-6,85x-14,5x-65,1x
Enterprise Value (EV) / FCF -47,8x-4,16x-5,01x-9,30x-43,4x
FCF Yield -2,09%-24,1%-20,0%-10,8%-2,30%
Price to Book -----
Nbr of stocks (in thousands) 3 246 7274 410 5344 398 6494 398 649-
Reference price () 0,270,060,030,030,03
Announcement Date 04/15/202104/01/2022---
1 CHF in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023 2024
Net sales1 -4,4912,023,044,0
EBITDA1 -20,3-32,3-19,0-9,00-2,00
Operating profit (EBIT)1 -20,3-34,3-21,0-11,0-4,00
Operating Margin --764%-175%-47,8%-9,09%
Pre-Tax Profit (EBT) -----
Net income -----
Net margin -----
EPS -----
Free Cash Flow1 -18,3-66,0-26,0-14,0-3,00
FCF margin --1 469%-217%-60,9%-6,82%
FCF Conversion 90,0%204%137%156%150%
Dividend per Share -----
Announcement Date 04/15/202104/01/2022---
1 CHF in Million
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt -----
Net Cash position -----
Leverage (Debt / EBITDA) -----
Free Cash Flow1 -18,3-66,0-26,0-14,0-3,00
ROE (Net Profit / Equities) -19,2%-27,9%-15,0%-7,00%-3,00%
Shareholders' equity -----
ROA (Net Profit / Asset) -----
Assets -----
Book Value Per Share -----
Cash Flow per Share -----
Capex -----
Capex / Sales -----
Announcement Date 04/15/202104/01/2022---
1 CHF in Million
Estimates
Key data
Capitalization (CHF) 130 200 024
Capitalization (USD) 141 282 200
Net sales (CHF) 4 492 000
Net sales (USD) 4 874 344
Number of employees 10
Sales / Employee (CHF) 449 200
Sales / Employee (USD) 487 434
Free-Float 71,7%
Free-Float capitalization (CHF) 93 364 118
Free-Float capitalization (USD) 101 310 948
Avg. Exchange 20 sessions (CHF) 173 098
Avg. Exchange 20 sessions (USD) 187 832
Average Daily Capital Traded 0,13%
EPS & Dividend